Adaptimmune Therapeutics (NASDAQ:ADAP) Given New $3.00 Price Target at HC Wainwright
Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) had its target price decreased by HC Wainwright from $3.50 to $3.00 in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also weighed in on ADAP. Scotiabank reduced their price objective […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) had its target price decreased by HC Wainwright from $3.50 to $3.00 in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also weighed in on ADAP. Scotiabank reduced their price objective […]
